- Source: AB-PINACA
AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012.
It was originally developed by Pfizer in 2009 as an analgesic medication.
AB-PINACA acts as a potent agonist for the CB1 receptor (Ki = 2.87 nM, EC50 = 1.2 nM) and CB2 receptor (Ki = 0.88 nM, EC50 = 2.5 nM) and fully substitutes for Δ9-THC in rat discrimination studies, while being 1.5x more potent.
There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.
Legal status
= Germany
=AB-PINACA is an Anlage II controlled substance in Germany as of November 2014.
= Singapore
=It is listed in the Fifth Schedule of the Misuse of Drugs Act and so is illegal in Singapore, as of May 2015.
= United States
=It is a Schedule I controlled substance in the United States.
= China
=It is a controlled substance in China as of October 2015.
= France
=It is a controlled substance in France as of March 2017.
See also
References
Kata Kunci Pencarian:
- AB-PINACA
- 5F-AB-PINACA
- MDMB-4en-PINACA
- AB-FUBINACA
- ADB-PINACA
- AB-CHMINACA
- 5F-ADB
- AB-PICA
- Synthetic cannabinoids
- List of designer drugs
